Theriva Biologics
TOVX
20 hedge funds and large institutions have $452K invested in Theriva Biologics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
11% more funds holding
Funds holding: 18 → 20 (+2)
0% less ownership
Funds ownership: 0.25% → 0.25% (-0%)
21% less capital invested
Capital invested by funds: $573K → $452K (-$120K)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$28.5K |
| 2 |
VF
Virtu Financial
New York
|
+$19.3K |
| 3 |
Jane Street
New York
|
+$14.9K |
| 4 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
+$5.41K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$72K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$8.61K |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$6.78K |
| 4 |
BlackRock
New York
|
-$62 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$49 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| – | -$8 | -1 | Closed |
|
TOVX Hedge Fund Activity: Q4 2023 in Review
20 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2023, worth a combined $452K — down 21% from $573K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TOVX positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $28.5K. The largest seller was Vanguard Group, cutting an estimated $72K.
- 20 institutional investors held Theriva Biologics (TOVX) as of Q4 2023, up from 18 in Q3 2023.
- Funds reported $452K of Theriva Biologics stock for Q4 2023, down 21% quarter-over-quarter.
- 6 funds opened new Theriva Biologics positions in Q4 2023 and 4 closed out, a net change of +2 holders.
- The largest Theriva Biologics buyer in Q4 2023 was Citadel Advisors, an estimated $28.5K added.
- The largest Theriva Biologics seller in Q4 2023 was Vanguard Group, an estimated $72K sold.
Based on aggregated 13F filings for Q4 2023.